MicroRNA-365a-3p inhibits c-Rel-mediated NF-κB signaling and the progression of pancreatic cancer.


Journal

Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053

Informations de publication

Date de publication:
28 06 2019
Historique:
received: 16 11 2018
revised: 19 03 2019
accepted: 19 03 2019
pubmed: 27 3 2019
medline: 27 2 2020
entrez: 27 3 2019
Statut: ppublish

Résumé

NF-κB contributes to the aggressiveness of pancreatic ductal adenocarcinoma (PDA), which is counteracted by the bioactive agent sulforaphane. We investigated sulforaphane-induced microRNA signaling and its influence on progression features. Using established cell lines, microRNA and gene arrays, we predicted miR-365a as the top candidate for the sulforaphane-induced inhibition of the NF-κB subunit c-Rel. The lipofection of miR-365a-3p mimics inhibited the luciferase activity of a c-Rel 3'-UTR construct, as well as c-Rel expression, NF-κB activity, and tumor viability, migration, and clonogenicity, whereas apoptosis was induced. In vivo, miR-365a-3p reduced the volume of tumor xenografts and the expression of progression markers. In a tissue array, the expression of miR-365a-3p was absent in almost all 91 malignant tissues but not in 5 normal tissues, thus confirming the previous results. Our observations suggest that sulforaphane-induced miR-365a-3p expression inhibits NF-κB activity by downregulating c-Rel, which prevents the progression of PDA.

Identifiants

pubmed: 30910589
pii: S0304-3835(19)30181-8
doi: 10.1016/j.canlet.2019.03.025
pii:
doi:

Substances chimiques

Anticarcinogenic Agents 0
Isothiocyanates 0
MIRN365 microRNA, human 0
MicroRNAs 0
Proto-Oncogene Proteins c-rel 0
REL protein, human 0
RELA protein, human 0
Sulfoxides 0
Transcription Factor RelA 0
sulforaphane GA49J4310U

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

203-212

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Libo Yin (L)

Molecular OncoSurgery, Section Surgical Research, Department of General, Visceral & Transplant Surgery, University of Heidelberg, Heidelberg, Germany. Electronic address: Yin@uni-heidelberg.de.

Xi Xiao (X)

Molecular OncoSurgery, Section Surgical Research, Department of General, Visceral & Transplant Surgery, University of Heidelberg, Heidelberg, Germany. Electronic address: xiaoxidaidai@outlook.com.

Christina Georgikou (C)

Molecular OncoSurgery, Section Surgical Research, Department of General, Visceral & Transplant Surgery, University of Heidelberg, Heidelberg, Germany. Electronic address: georgikou@uni-heidelberg.de.

Yefeng Yin (Y)

Molecular OncoSurgery, Section Surgical Research, Department of General, Visceral & Transplant Surgery, University of Heidelberg, Heidelberg, Germany. Electronic address: yefeng541009@gmail.com.

Li Liu (L)

Molecular OncoSurgery, Section Surgical Research, Department of General, Visceral & Transplant Surgery, University of Heidelberg, Heidelberg, Germany. Electronic address: l.liu@uni-heidelberg.de.

Svetlana Karakhanova (S)

Molecular OncoSurgery, Section Surgical Research, Department of General, Visceral & Transplant Surgery, University of Heidelberg, Heidelberg, Germany. Electronic address: karakhanova@uni-heidelberg.de.

Yiqiao Luo (Y)

Molecular OncoSurgery, Section Surgical Research, Department of General, Visceral & Transplant Surgery, University of Heidelberg, Heidelberg, Germany. Electronic address: Luo@uni-heidelberg.de.

Jury Gladkich (J)

Molecular OncoSurgery, Section Surgical Research, Department of General, Visceral & Transplant Surgery, University of Heidelberg, Heidelberg, Germany. Electronic address: gladkich@uni-heidelberg.de.

Joerg Fellenberg (J)

Research Centre for Experimental Orthopedics, Clinic for Orthopedics and Trauma Surgery, University of Heidelberg, Germany.

Carsten Sticht (C)

Medical Research Centre, Medical Faculty Mannheim, University of Heidelberg, Germany. Electronic address: carsten.sticht@medma.uni-heidelberg.de.

Norbert Gretz (N)

Medical Research Centre, Medical Faculty Mannheim, University of Heidelberg, Germany. Electronic address: Norbert.Gretz@medma.uni-heidelberg.de.

Wolfgang Gross (W)

Molecular OncoSurgery, Section Surgical Research, Department of General, Visceral & Transplant Surgery, University of Heidelberg, Heidelberg, Germany. Electronic address: WGross@uni-hd.de.

Ingrid Herr (I)

Molecular OncoSurgery, Section Surgical Research, Department of General, Visceral & Transplant Surgery, University of Heidelberg, Heidelberg, Germany. Electronic address: i.herr@uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH